Skip to main content
Clinical Trials/NCT01837108
NCT01837108
Completed
Phase 4

Effects of the Selective Mineralocorticoid Receptor Antagonist Eplerenone on Extracellular Adenosine Formation in Humans in Vivo

Radboud University Medical Center1 site in 1 country14 target enrollmentApril 2013

Overview

Phase
Phase 4
Intervention
Placebo
Conditions
Pharmacodynamics
Sponsor
Radboud University Medical Center
Enrollment
14
Locations
1
Primary Endpoint
forearm blood flow response
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

Various studies have reported cardioprotective effects of mineralocorticoid receptor (MR) antagonists in the setting of an acute myocardial infarction. In a recent animal study, the protective effect of MR antagonists on infarct size was completely abolished in CD73 knock-out and adenosine A2b receptor knock-out mice, and by co-administration of adenosine receptor antagonists in rats. These findings suggest that extracellular formation of adenosine is crucial for this protective effect and that MR antagonists stimulate extracellular adenosine formation by the enzyme CD73.

To investigate whether eplerenone promotes adenosine receptor stimulation by activating CD73, the investigators will measure forearm blood flow in response to various dosages of dipyridamole with the use of plethysmography. Dipyridamole increases the extracellular endogenous adenosine concentration by inhibition of the ENT transporter and induces local vasodilation. Therefore, the vasodilator effect of dipyridamole accurately reflects extracellular adenosine formation by the CD73 enzyme.

Registry
clinicaltrials.gov
Start Date
April 2013
End Date
January 2014
Last Updated
12 years ago
Study Type
Interventional
Study Design
Crossover
Sex
Male

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age 18-40 years
  • Written informed consent

Exclusion Criteria

  • Hypertension (Blood pressure \>140 mmHg and/or \>90 mmHg - SBP/DBP-)
  • Hypotension (Blood pressure \<100 mmHg and/or \<60 mmHg -SBP/DBP-)
  • Diabetes Mellitus (fasting glucose \> 6.9 mmol/L or random \> 11.0 mmol/L in venous plasma)
  • History of any cardiovascular disease
  • Angina pectoris
  • History of chronic obstructive pulmonary disease (COPD) or asthma
  • Alcohol and/or drug abuse
  • Concomitant use of medication
  • Renal dysfunction (MDRD \< 60 ml/min/1.73 m2)
  • Liver enzyme abnormalities (ALAT \> twice upper limit of normality)

Arms & Interventions

Placebo

fully mimicking placebo 50 mg bid during 8 days

Intervention: Placebo

eplerenone

eplerenone 50 mg bid during 8 days

Intervention: Eplerenone

Outcomes

Primary Outcomes

forearm blood flow response

Time Frame: 8 days

Forearm blood flow response to the intrabrachial administration of incremental dosages of dipyridamole, after treatment with eplerenone, compared to placebo. The forearm blood flow will be measured by plethysmography.

Secondary Outcomes

  • forearm blood flow(8 days)

Study Sites (1)

Loading locations...

Similar Trials